Sunshine and Rash: Testing the Role of Sunscreen to Prevent Epidermal Growth Factor Receptor Inhibitor–Induced Rash
- 30 September 2007
- journal article
- review article
- Published by Elsevier BV in Supportive Cancer Therapy
- Vol. 4 (4), 198-202
- https://doi.org/10.3816/sct.2007.n.015
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinibPhotodermatology, Photoimmunology & Photomedicine, 2007
- PhotoprotectionJournal of the American Academy of Dermatology, 2005
- Chemoprevention of UV Light-Induced Skin Tumorigenesis by Inhibition of the Epidermal Growth Factor ReceptorCancer Research, 2005
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Epidermal Growth Factor Receptor-dependent Control of Keratinocyte Survival and Bcl-xL Expression through a MEK-dependent PathwayOnline Journal of Public Health Informatics, 2001
- Has the sun protection factor had its day?BMJ, 2000
- Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trialThe Lancet, 1999
- UV activates growth factor receptors via reactive oxygen intermediates.The Journal of cell biology, 1996
- Involvement of growth factor receptors in the mammalian UVC responseCell, 1994